Business Description
Eterna Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1140822099
Share Class Description:
ERNA: Ordinary SharesDescription
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.13 | |||||
| Equity-to-Asset | -5.88 | |||||
| Debt-to-Equity | -0.74 | |||||
| Debt-to-EBITDA | -0.86 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -59 | |||||
| Beneish M-Score | -1.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -2.9 | |||||
| 3-Year EPS without NRI Growth Rate | -4.8 | |||||
| 3-Year FCF Growth Rate | 0.7 | |||||
| 3-Year Book Growth Rate | -51.8 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 5.7 | |||||
| 9-Day RSI | 12.91 | |||||
| 14-Day RSI | 19.48 | |||||
| 6-1 Month Momentum % | -50.92 | |||||
| 12-1 Month Momentum % | 2.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.48 | |||||
| Quick Ratio | 0.48 | |||||
| Cash Ratio | 0.43 | |||||
| Days Payable | 4046.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -37.6 | |||||
| Shareholder Yield % | -98.88 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.91 | |||||
| Operating Margin % | -3397.49 | |||||
| Net Margin % | -7513.88 | |||||
| FCF Margin % | -2896.49 | |||||
| ROA % | -109.46 | |||||
| ROIC % | -52.8 | |||||
| ROC (Joel Greenblatt) % | -143.78 | |||||
| ROCE % | -127.14 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.36 | |||||
| EV-to-EBIT | -1.3 | |||||
| EV-to-EBITDA | -1.37 | |||||
| EV-to-Revenue | 89.19 | |||||
| EV-to-FCF | -3.08 | |||||
| Earnings Yield (Greenblatt) % | -76.92 | |||||
| FCF Yield % | -76.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ERNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eterna Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.598 | ||
| EPS (TTM) ($) | -8.31 | ||
| Beta | 2.28 | ||
| Volatility % | 134.93 | ||
| 14-Day RSI | 19.48 | ||
| 14-Day ATR ($) | 0.117407 | ||
| 20-Day SMA ($) | 0.85169 | ||
| 12-1 Month Momentum % | 2.12 | ||
| 52-Week Range ($) | 0.4339 - 2.625 | ||
| Shares Outstanding (Mil) | 51.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eterna Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eterna Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eterna Therapeutics Inc Frequently Asked Questions
What is Eterna Therapeutics Inc(ERNA)'s stock price today?
The current price of ERNA is $0.44. The 52 week high of ERNA is $2.63 and 52 week low is $0.43.
When is next earnings date of Eterna Therapeutics Inc(ERNA)?
The next earnings date of Eterna Therapeutics Inc(ERNA) is 2025-02-12 Est..
Does Eterna Therapeutics Inc(ERNA) pay dividends? If so, how much?
Eterna Therapeutics Inc(ERNA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers